Using dosing guided by phase I pharmacokinetic studies in US men [10], prospective treatment of men on a phase II trial with genistein for one month prior to radical prostatectomy for localized PCa demonstrated that genistein decreases MMP-2 expression in human prostate epithelial cells [2]. The gene discussed is MMP2; the disease is posterior cortical atrophy.